Pharmaceutical products

Tender description

Invitation to offer for National Framework Agreement for the Supply of Generic Pharmaceuticals — Tenofovir Disoproxil/Emtricitabine and Tenofovir Disoproxil/Emtricitabine/Efavirenz. Offer reference number: CM/PHG/17/5545 Period of Framework Agreement: the total maximum duration of the Framework Agreement to be no more than 36 months. Potential periods of call-offs under the Framework Agreement: — North West London: 21.5.2019 to 31.10.2020 (18 months), — North Central and East London: 21.5.2019 to 31.10.2020 (18 months), — South East and West London: 21.5.2019 to 31.10.2020 (18 months), — North of England: 21.5.2019 to 31.10.2020 (18 months), — Midlands and East: 21.5.2019 to 31.10.2020 (18 months), — South of England: 21.5.2019 to 31.10.2020 (18 months). Lot 1a: London: Tenofovir Disoproxil/Emtricitabine. Offer reference number: CM/PHG/17/5545/01 Lot 1b: London: Tenofovir Disoproxil/Emtricitabine/Efavirenz. Offer reference number: CM/PHG/17/5545/02 Period of Framework Agreement: the total maximum duration of the Framework Agreement to be no more than 36 months. Potential periods of call-offs under the Framework Agreement: — North West London: 21.5.2019 to 31.10.2020 (18 months), — North Central and East London: 21.5.2019 to 31.10.2020 (18 months), — South East and West London: 21.5.2019 to 31.10.2020 (18 months). Lot 2a: Rest of England: Tenofovir Disoproxil/Emtricitabine Offer reference number: CM/PHG/17/5545/03 Lot 2b: Rest of England: Tenofovir Disoproxil/Emtricitabine/Efavirenz. Offer reference number: CM/PHG/17/5545/04 Period of Framework Agreement: the total maximum duration of the Framework Agreement to be no more than 36 months. Potential periods of call-offs under the Framework Agreement: — North of England: 21.5.2019 to 31.10.2020 (18 months), — Midlands and East: 21.5.2019 to 31.10.2020 (18 months), — South of England: 21.5.2019 to 31.10.2020 (18 months).